Clincosm LogoSign in Get a demo

Research of Molecular and Metabolic Markers in Oligodendrogliomas Comparatively to Other Brain Tumours

Sponsor
University Hospital, Strasbourg, France (Other)
Overall Status
Completed
CT.gov ID
NCT00213876
Collaborator
(none)
189
Enrollment
1
Location
90
Duration (Months)
2.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

At present, diagnosis of oligodendroglioma is made on histological and radiographic criteria in the French Mayo-Ste Anne classification. The less frequent grade A oligodendrogliomas are characterized by no vascular contrast on RMN evaluation comparatively to grade B forms. This benign histological subtype relapses in few cases with a more aggressive histology. To determine these relapsed cases at diagnosis, a collection of tumour begun in February 2004. Then, our study was designed to identify diagnostic molecular and metabolic markers that could eventually be used as a signature characterising grade A versus grade B oligodendrogliomas. The molecular analysis will use genomic techniques like allelotyping study, quantitative real-time PCR, gene sequencing , serial analysis of genomic expression and immunohistochemistry, since the metabolic study will be the spectroscopic examination of in vivo tumour. This study will include paediatric and adult patients followed for oligodendrogliomas, medulloblastomas and gliomas to compare the different tumour signatures. All these results will be correlated to survival and clinical features.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    189 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Prospective
    Official Title:
    Research of Molecular and Metabolic Diagnostic Markers in Oligodendrogliomas A and B Comparatively.
    Study Start Date :
    Feb 1, 2004
    Actual Study Completion Date :
    Aug 1, 2011

    Outcome Measures

    Primary Outcome Measures

      Eligibility Criteria

      Criteria

      Ages Eligible for Study:
      1 Year and Older
      Sexes Eligible for Study:
      All
      Accepts Healthy Volunteers:
      No
      Inclusion Criteria:

      • Paediatric and adult patients (> 1 year of age)

      • Patient with oligodendroglioma or medulloblastoma or glioma

      • Possibility of 3 year follow-up

      • Patient consent obtained

      Exclusion Criteria:

      Contacts and Locations

      Locations

      Site City State Country Postal Code
      1 Natacha Entz-Werle Strasbourg France

      Sponsors and Collaborators

      • University Hospital, Strasbourg, France

      Investigators

      • Principal Investigator: Natacha Entz-Werle, MD, Hopitaux Universitaires de Strasbourg

      Study Documents (Full-Text)

      None provided.

      More Information

      Publications

      None provided.
      Responsible Party:
      , ,
      ClinicalTrials.gov Identifier:
      NCT00213876
      Other Study ID Numbers:
      • 3154
      First Posted:
      Sep 21, 2005
      Last Update Posted:
      Aug 30, 2011
      Last Verified:
      Aug 1, 2011
      Keywords provided by , ,
      Brain tumours
      oligodendrogliomas
      allelotyping
      SAGE
      Presence of molecular abnormalities statistically linked to survival or response to chemotherapy
      Additional relevant MeSH terms:
      Oligodendroglioma

      Study Results

      No Results Posted as of Aug 30, 2011